NewAmsterdam Pharma Co N.V.
NAMSW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 9 institutions reported holding it in 13F filings for Q2 2026, worth $28.1M in total; no superinvestor holds it.
Other share classesNAMS
13F holders, Q1 2025
Institutional positions in NewAmsterdam Pharma Co N.V. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- −1 vs. Q4 2024
- Shares held
- 1.31M
- −13.5K (−1.0%) vs. Q4 2024
- Total value
- $12.3M
- −$6.43M (−34.3%) vs. Q4 2024
- New holders
- 0
- 1 more added
- Sold out
- 1
- 2 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NAMSW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $28.1M |
| Q1 2026 | 9 | $26.0M |
| Q4 2025 | 9 | $29.9M |
| Q3 2025 | 9 | $22.2M |
| Q2 2025 | 10 | $10.4M |
| Q1 2025 | 10 | $12.3M |
| Q4 2024 | 11 | $18.8M |
| Q3 2024 | 11 | $9.32M |
| Q2 2024 | 10 | $11.5M |
| Q1 2024 | 11 | $15.9M |
| Q4 2023 | 18 | $5.65M |
| Q3 2023 | 19 | $3.49M |
| Q2 2023 | 19 | $4.73M |
| Q1 2023 | 19 | $5.00M |
| Q4 2022 | 22 | $4.53M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 1 | $35.5K |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding NewAmsterdam Pharma Co N.V.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 500,333 | $4.50M | 0.21% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 333,333 | $3.00M | 0.05% | 00.0% | Unchanged |
| Affinity Asset Advisors, LLC | 241,957 | $2.75M | 0.43% | +4,022+1.7% | Added |
| Bain Capital Life Sciences Investors, LLC | 100,000 | $899.0K | 0.13% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 92,787 | $834.2K | 0.02% | 00.0% | Unchanged |
| Laurion Capital Management LP | 16,666 | $149.8K | 0.01% | 00.0% | Unchanged |
| Vestcor Inc | 9,632 | $91.0K | 0.00% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 8,884 | $79.9K | 0.00% | −3,809−30.0% | Reduced |
| UBS Group AG | 2,381 | $21.4K | 0.00% | −100−4.0% | Reduced |
| CIBC Private Wealth Group, LLC | 1,000 | $6.15K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 0 | $0 | 0.00% | −13,655−100.0% | Sold out |